drugset / Press release
BioXcel Therapeutics Announces Primary and Secondary Endpoints Met in Two Pivotal Phase 3 Trials of BXCL501 for the Acute Treatment of Agitation in Patients with Schizophrenia and Bipolar Disorder
2020-07-20 · BioXcel Therapeutics Inc · original bioxceltherapeutics.com ↗
Highly statistically significant improvements in PEC score observed vs. placebo (p<0.0001) at two hours in the SERENITY trials for both doses tested
The release as fetched from its publisher. bioxceltherapeutics.com ↗